Intensive statin therapy in coronary artery disease: is lower cholesterol better and safe?
Primary- and secondary-prevention trials involving subjects with or at risk for coronary artery disease have previously demonstrated a beneficial effect of conventional-dose statin therapy. Recent trials of high-dose statin therapy in subjects with stable coronary disease or acute coronary syndromes have yielded conflicting results. The aim of this narrative article is to provide a critical and up-to-date summary of the findings of clinical trials of intensive statin therapy, including a brief overview of the safety and efficacy of such treatments.
Seshasai
Sreenivasa R K
SR
Molecular Epidemiology Unit, Strangeways Research Laboratory, Worts Causeway, Cambridge, CB1 8RN, UK. srk36@medschl.cam.ac.uk
Ray
Kausik K
KK
D002784:Cholesterol / Q000097:blood*; D003324:Coronary Artery Disease / Q000097:blood / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002784:Cholesterol